fbpx
Listen

Arab Company for Drugs Ltd

Arab Company for Drugs Ltd

Icon

The company was established in 2007, and commercial production commenced on April 2019. The company aims to contribute to the development of the pharmaceutical sector in Sudan and the region through the provision of drugs and services necessary to help in the fight against diseases, by means of the production, packaging and marketing of human and veterinary drugs; the production, effective promotion and distribution of high-quality pharmaceutical products, with excellent customer services; and increased export to neighboring countries, such as Chad, Ethiopia, Eritrea, South Sudan and some Arab countries.

Icon

Soba area, Block 11, 20 km south of Khartoum- Republic of the Sudan

Contact address
  • Icon (+249) 155 662005
  • Icon (+249) 183 740636
  • Icon acvmsudan@gmail.com
  • Icon P.O. Box11354, Khartoum
  • Icon www.kaswaco.com
Icon
Designed capacity

The company aims to produce, market and distribute pharmaceutical medicines through three production lines, as follows:

  • – Injectable line at a capacity of 900,000 liters per year
  • – Oral liquid line at a capacity of 1,800,000 liters per year
  • – Powders and tablets line at a capacity of 180,000 kg per year
  • – During 2017, the production of human medicines was added to the company’s objectives

Icon
Capital and shareholders

The subscribed and paid-up capital is US$51 million, and shareholders are:

  • – AAAID: 32.53%
  • – Arab Company for Pharmaceutical Industries (ACDIMA): 40%
  • – The Arab Company for Industrial Investments: 15.86%
  • – Industrial Development Bank: 6.47%
  • – Veterinary Supplies Corporation: 3.44%
  • – Government of South Darfur State: 1.7%

  • AAAID

  • Arab Company for Pharmaceutical Industries (ACDIMA)

  • The Arab Company for Industrial Investments

  • Industrial Development Bank

  • Veterinary Supplies Corporation

  • Government of South Darfur State

Icon
Average sales

The company's average sales for the last 3 years is approximately SDG 583 million

Icon
Market share

Estimated to reach 30%

Icon
Company products

1. Injectables
- Oxytar 50- Oxytar200 (Oxytetracycline 5% & 20%)
- Taylar 200 (Tylosin 20%)
- Ivermar (Invermectin injection 1%)
- Enroxar (Enrofloxacin injection)
- Gentar 10 - Gentar 20 (Gentamycin 0.2 & 0.4%)
- Dexar 2- Dexar 4 (Dexamethasone 0.2% & 0.4%)
- Sulfar 333 (Sulfa 33.3 inj.)
- Diminzar (Antipyrine + Diminazine + B12)
- AD3E (Vitamin AD3E)
- Septar (Sulphadiazine + Trimethoprim)
- Closar (Closentel 10%)

2. Oral Liquid Solutions
- Albenar 25 (Albendazole 2.5%)
- Albenar 100 (Albendazole 10%)
- Ivermar Drench (Ivermectin 0.8%)
- Levoxar Plus (Levamisole + Oxyclozanide)
- Refinar (Rafoxinide + Fendbendazole)

3. Solid Orals
- Oxytar 50% WS (Oxytetracycline 50%)
- Tetrazar 10-30% (Tetramyzole 10% & 30%)
- Gentar 250 WS (Gentamycin 25%)
- Gentadoxar WS (Gentamycinn + Doxyclin)
- Doxar 500 WS (Doxyclin 50)
- Colistr WS (Colistin 4800)
- Albenar 300 Bolus (Albendazole 300 mg)
- Albenar Bolus Plus (Albendazole + Sodium Selenite)
- Levoxar Bolus (Levamezole + Oxclozanide)
- Oxytar Bolus (Oxytetracycline 500 mg)